Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
PfizerPFE |
$440,000 |
 |
Johnson & JohnsonJNJ |
-$120M |
 |
Mind Medicine (MindMed)MNMD |
-$86M |
 |
ModernaMRNA |
-$37.4B |
 |
AbbVieABBV |
-$792M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Downing Cristal N | Nov 10, 2025 | Sell | 7,085 | $87 | $620,000 |
| Williams David Michael | Nov 3, 2025 | Sell | 8,614 | $83.5895 | $720,000 |
| Smart Dalton E. III | Apr 25, 2025 | Sell | 4,262 | $82.76 | $350,000 |
| Oosthuizen Johannes Jacobus | Feb 19, 2025 | Sell | 8,500 | $84.0876 | $710,000 |
| Williams David Michael | Feb 13, 2025 | Sell | 6,000 | $85.3428 | $510,000 |
| THULIN INGE G | Feb 6, 2025 | Buy | 2,833 | $88.25 | $250,000 |
| Downing Cristal N | Feb 6, 2025 | Sell | 2,361 | $88.7551 | $210,000 |
| BAKER DOUGLAS M JR | Feb 5, 2025 | Buy | 15,000 | $88.5 | $1.3M |
| Litchfield Caroline | Feb 14, 2024 | Sell | 38,291 | $125.5 | $4.8M |
| Davis Robert M | Feb 14, 2024 | Sell | 85,021 | $125.3993 | $11M |
| Davis Robert M | Feb 13, 2024 | Sell | 25,324 | $126.3733 | $3.2M |
| Davis Robert M | Feb 13, 2024 | Sell | 124,676 | $125.7431 | $16M |
| Romanelli Joseph | Feb 13, 2024 | Sell | 1,000 | $124.8879 | $120,000 |
| Li Dean Y | Feb 9, 2024 | Sell | 14,702 | $125.4988 | $1.8M |
| Williams David Michael | Feb 7, 2024 | Sell | 1,451 | $127.5729 | $190,000 |
| Oosthuizen Johannes Jacobus | Feb 2, 2024 | Sell | 18,959 | $127.175 | $2.4M |
| MIZELL STEVEN | Feb 2, 2024 | Sell | 50,694 | $126.6491 | $6.4M |
| Zachary Jennifer | Feb 2, 2024 | Sell | 49,499 | $126.9678 | $6.3M |
FAQ - Insider Transactions
The most recent insider transaction for Merck & Company was conducted by Downing Cristal N, who sold 7,085 shares on November 10, 2025 at a price of $87.00 per share.
BAKER DOUGLAS M JR has bought the most MRK stock in the last 2 years, with a total value of $1.3M.
Davis Robert M has sold the most MRK stock in the last 2 years, with a total value of $30M.
The total value of insider transactions for Merck & Company in the last 2 years is negative, amounting to -$53M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Merck & Company have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
